Literature DB >> 6154128

A comparison of New World alphaviruses in the western equine encephalomyelitis complex by immunochemical and oligonucleotide fingerprint techniques.

D W Trent, J A Grant.   

Abstract

We have examined the molecular basis for the observed antigenic differences between isolates of western equine encephalomyelitis (WEE) virus and those of a serologically related alphavirus from the eastern United States designated Highlands J (HJ). The structural proteins of WEE virus isolates have mol. wt. of 55 x 10(3) (E1), 47 x 10(3) (E2) and 33 x 10(3) for the nucleocapsid. The E1 glycoprotein had an isoelectric point (pI) of 6.4 and induced haemagglutination-inhibiting (HI) antibody which was specific for WEE virus. The E2 glycoprotein of WEE virus had a pI of 8.4 and induced antibody which was virus specific by neutralization (PRNT) but cross-reacted with HJ virus in the radioimmune precipitation (RIP) test. Envelope glycoproteins of HJ virus isolates had mol. wt. of 58 x 10(3) (E1) and 49 x 10(3) EW) respectively. The E1 glycoprotein from HJ virus had a pI of 6.8 and induced antibody which reacted specifically in the HI, PRNT and RIP tests. Isolated E2 protein of HJ virus had a pI of 9.1 and induced antibodies which were reactive at equal titre with both WEE and HJ viruses by RIP. Two-dimensional gel electrophoresis of RNase T1 oligonucleotides of WEE virus and HJ virus genome RNase T1 oligonucleotides revealed that the primary structures of the RNAs of these two serologically related alphaviruses were very distant. The fingerprints of the oligonucleotides from 16 WEE viruses from western and central North America, Mexico and South America were similar to each other and easily distinguished from those of the eight HJ viruses isolated in the eastern United States from Massachusetts to Louisiana.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6154128     DOI: 10.1099/0022-1317-47-2-261

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  9 in total

1.  Impact of climate on western equine encephalitis in Manitoba, Minnesota and North Dakota, 1980-1983.

Authors:  R F Sellers; A R Maarouf
Journal:  Epidemiol Infect       Date:  1988-12       Impact factor: 2.451

2.  An evolutionary tree relating eight alphaviruses, based on amino-terminal sequences of their glycoproteins.

Authors:  J R Bell; R M Kinney; D W Trent; E G Strauss; J H Strauss
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

3.  Genetic heterogeneity among isolates of Ross River virus from different geographical regions.

Authors:  M D Lindsay; R J Coelen; J S Mackenzie
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

4.  Rubella virion polypeptides: characterization by polyacrylamide gel electrophoresis, isoelectric focusing and peptide mapping.

Authors:  L Ho-Terry; A Cohen
Journal:  Arch Virol       Date:  1982       Impact factor: 2.574

5.  Recent vesicular stomatitis virus infection detected by immunoglobulin M antibody capture enzyme-linked immunosorbent assay.

Authors:  S D Vernon; P A Webb
Journal:  J Clin Microbiol       Date:  1985-10       Impact factor: 5.948

6.  Recombinational history and molecular evolution of western equine encephalomyelitis complex alphaviruses.

Authors:  S C Weaver; W Kang; Y Shirako; T Rumenapf; E G Strauss; J H Strauss
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

Review 7.  The alphaviruses: gene expression, replication, and evolution.

Authors:  J H Strauss; E G Strauss
Journal:  Microbiol Rev       Date:  1994-09

Review 8.  Medically important arboviruses of the United States and Canada.

Authors:  C H Calisher
Journal:  Clin Microbiol Rev       Date:  1994-01       Impact factor: 26.132

9.  Identification of salivary gland escape barriers to western equine encephalitis virus in the natural vector, Culex tarsalis.

Authors:  Charles B Stauft; Aaron T Phillips; Tony T Wang; Kenneth E Olson
Journal:  PLoS One       Date:  2022-03-17       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.